127 results
8-K
EX-10.2
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.1
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
EX-10.1
SKYE
Skye Bioscience Inc
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
EX-10.2
SKYE
Skye Bioscience Inc
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
EX-10.2
SKYE
Skye Bioscience Inc
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.1
4zrg9hx ti3pt53f
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
EX-10.1
o28nxb3emksqht 3w1
3 Oct 23
Departure of Directors or Certain Officers
4:34pm
8-K
EX-10.4
5swc05gj
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.3
3d9gpw9
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.1
i2mze8djkomaqgvs47xw
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.2
ev2ynlmivlr
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K
EX-10.1
wusu yd5h
23 Feb 23
Entry into a Material Definitive Agreement
5:18pm
8-K
EX-10.1
rm4o3z2z5 0h
15 Feb 23
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
4:26pm
8-K
EX-10.1
npu2ip
26 Jan 23
Entry into a Material Definitive Agreement
9:22pm
8-K
EX-10.1
kd6z4e3vxu9hp9ohbb
6 Jan 23
Entry into a Material Definitive Agreement
4:57pm
8-K
EX-10.1
vig46r4jex6
16 Dec 22
Entry into a Material Definitive Agreement
6:40pm
8-K
EX-10.1
jg7av
23 Nov 22
Entry into a Material Definitive Agreement
5:23pm